We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors.
- Authors
Wild, Damian; Bomanji, Jamshed B; Benkert, Pascal; Maecke, Helmut; Ell, Peter J; Reubi, Jean Claude; Caplin, Martyn E
- Abstract
Somatostatin receptor PET tracers such as [(68)Ga-DOTA,1-Nal(3)]-octreotide ((68)Ga-DOTANOC) and [(68)Ga-DOTA,Tyr(3)]-octreotate ((68)Ga-DOTATATE) have shown promising results in patients with neuroendocrine tumors, with a higher lesion detection rate than is achieved with (18)F-fluorodihydroxyphenyl-l-alanine PET, somatostatin receptor SPECT, CT, or MR imaging. (68)Ga-DOTANOC has high affinity for somatostatin receptor subtypes 2, 3, and 5 (sst2,3,5). It has a wider receptor binding profile than (68)Ga-DOTATATE, which is sst2-selective. The wider receptor binding profile might be advantageous for imaging because neuroendocrine tumors express different subtypes of somatostatin receptors. The goal of this study was to prospectively compare (68)Ga-DOTANOC and (68)Ga-DOTATATE PET/CT in the same patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and to evaluate the clinical impact of (68)Ga-DOTANOC PET/CT.
- Publication
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2013, Vol 54, Issue 3, p364
- ISSN
1535-5667
- Publication type
Journal Article
- DOI
10.2967/jnumed.112.111724